| Gene symbol | TERT | Synonyms | CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT, hEST2, hTRT | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5p15.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | telomerase reverse transcriptase | ||||
| GTO ID | GTC3639 |
| Trial ID | NCT06102525 |
| Disease | Glioblastoma |
| Altered gene | TERT |
| Therapeutic/Target gene | Target gene|Therapeutic gene |
| Therapy | Ribozyme |
| Treatment | RZ-001 |
| Co-treatment | VGCV |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, and Efficacy of RZ-001 in Combination With Valganciclovir in Subjects With Glioblastoma |
| Year | 2023 |
| Country | United States |
| Company sponsor | Ribozyome |
| Other ID(s) | RZ-001-201 |
| Vector information | |||||||||
|
|||||||||
| Cohort1: RZ-001_Dose 1 | |||||||||
|
|||||||||
| Cohort2: RZ-001_Dose 2 | |||||||||
|
|||||||||
| Cohort3: RZ-001_Dose 3 | |||||||||
|
|||||||||
| Cohort4: RZ-001_Dose 4 | |||||||||
|
|||||||||
| Cohort5: RZ-001_Dose 5 | |||||||||
|
|||||||||
| Cohort6: RZ-001_Dose 6 | |||||||||
|
|||||||||